{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T18:10:58Z","timestamp":1793815858935,"version":"4.6.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,10,30]],"date-time":"2021-10-30T00:00:00Z","timestamp":1635552000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,10,30]],"date-time":"2021-10-30T00:00:00Z","timestamp":1635552000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"unicocell biomed co. ltd."},{"DOI":"10.13039\/501100004725","name":"ministry of economic affairs","doi-asserted-by":"publisher","award":["105-EC-17-A-22-I5-0007"],"award-info":[{"award-number":["105-EC-17-A-22-I5-0007"]}],"id":[{"id":"10.13039\/501100004725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Stem Cell Res Ther"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>To evaluate the safety and efficacy of intra-articular (IA) injection of allogeneic adipose-derived stem cells (ADSCs) ELIXCYTE\u00ae for knee osteoarthritis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This was a patient-blind, randomized, active-control trial consisted of 4 arms including hyaluronic acid (HA) control and 3 ELIXCYTE\u00ae doses. A total of 64 subjects were screened, and 57 subjects were randomized. The primary endpoints included the changes from baseline to post-treatment visit of Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain score at Week 24 and the incidence of adverse events (AEs) and serious adverse events (SAEs).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>No ELIXCYTE\u00ae-related serious adverse events were reported during 96\u00a0weeks of follow-up and no suspected unexpected serious adverse reaction (SUSAR) or death was reported. The changes of the primary endpoint, WOMAC pain score at Week 24, showed significant differences in all ELIXCYTE\u00ae groups, as well as in HA groups between post-treatment visit and baseline. The ELIXCYTE\u00ae groups revealed significant decreases at Week 4 compared to HA group in WOMAC total scores, stiffness scores, functional limitation scores suggested the potential of ELIXCYTE\u00ae in earlier onset compared to those from HA. The significant differences of visual analog scale (VAS) pain score and Knee Society Clinical Rating System (KSCRS) functional activities score at Week 48 after ELIXCYTE\u00ae administration suggested the potential of ELIXCYTE\u00ae in the longer duration of the effectiveness compared to HA group.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>ELIXCYTE\u00ae for knee osteoarthritis treatment was effective, safe, and well-tolerated. The efficacy results were showed that ELIXCYTE\u00ae conferred the earlier onset of reductions in pain scores and improvements in functional scores than HA group.<\/jats:p>\n                <jats:p><jats:italic>Trial registration<\/jats:italic>: ClinicalTrials.gov Identifier: NCT02784964. Registered 16 May, 2016\u2014Retrospectively registered, <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02784964\">https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02784964<\/jats:ext-link><\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13287-021-02631-z","type":"journal-article","created":{"date-parts":[[2021,10,30]],"date-time":"2021-10-30T20:16:39Z","timestamp":1635624999000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":84,"title":["Treatment of knee osteoarthritis with intra-articular injection of allogeneic adipose-derived stem cells (ADSCs) ELIXCYTE\u00ae: a phase I\/II, randomized, active-control, single-blind, multiple-center clinical trial"],"prefix":"10.1186","volume":"12","author":[{"given":"Cheng-Fong","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Chien","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen-Te","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hung-Ta H.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Shin","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Pei","family":"Hung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Chu","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7369-0300","authenticated-orcid":false,"given":"Yuhan","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,30]]},"reference":[{"issue":"10264","key":"2631_CR1","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1016\/S0140-6736(20)32230-3","volume":"396","author":"DJ Hunter","year":"2020","unstructured":"Hunter DJ, March L, Chew M. Osteoarthritis in 2020 and beyond: a Lancet Commission. Lancet. 2020;396(10264):1711\u20132.","journal-title":"Lancet"},{"key":"2631_CR2","doi-asserted-by":"crossref","unstructured":"Ghouri A, Conaghan PG. Update on novel pharmacological therapies for osteoarthritis. Therapeutic advances in musculoskeletal disease. 2019;11:1759720x19864492.","DOI":"10.1177\/1759720X19864492"},{"issue":"10182","key":"2631_CR3","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1016\/S0140-6736(19)30417-9","volume":"393","author":"DJ Hunter","year":"2019","unstructured":"Hunter DJ, Bierma-Zeinstra S. Osteoarthritis. Lancet (London, England). 2019;393(10182):1745\u201359.","journal-title":"Lancet (London, England)"},{"issue":"9","key":"2631_CR4","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1080\/17425247.2020.1783234","volume":"17","author":"A Migliore","year":"2020","unstructured":"Migliore A, Paoletta M, Moretti A, Liguori S, Iolascon G. The perspectives of intra-articular therapy in the management of osteoarthritis. Exp Opin Drug Deliv. 2020;17(9):1213\u201326.","journal-title":"Exp Opin Drug Deliv"},{"issue":"5","key":"2631_CR5","doi-asserted-by":"publisher","first-page":"2697","DOI":"10.3390\/ijms22052697","volume":"22","author":"E Rezu\u015f","year":"2021","unstructured":"Rezu\u015f E, Burlui A, Cardoneanu A, Macovei LA, Tamba BI, Rezu\u015f C. From pathogenesis to therapy in knee osteoarthritis: bench-to-bedside. Int J Mol Sci. 2021;22(5):2697.","journal-title":"Int J Mol Sci"},{"key":"2631_CR6","doi-asserted-by":"crossref","unstructured":"Harrell CR, Markovic BS, Fellabaum C, Arsenijevic A, Volarevic V. Mesenchymal stem cell-based therapy of osteoarthritis: current knowledge and future perspectives. Biomed Pharmacother Biomed Pharmacother. 2019;109:2318\u201326.","DOI":"10.1016\/j.biopha.2018.11.099"},{"issue":"11","key":"2631_CR7","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.1016\/j.joca.2015.07.004","volume":"23","author":"YM Pers","year":"2015","unstructured":"Pers YM, Ruiz M, No\u00ebl D, Jorgensen C. Mesenchymal stem cells for the management of inflammation in osteoarthritis: state of the art and perspectives. Osteoarthritis Cartilage. 2015;23(11):2027\u201335.","journal-title":"Osteoarthritis Cartilage"},{"issue":"10","key":"2631_CR8","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1038\/nrrheum.2013.109","volume":"9","author":"F Barry","year":"2013","unstructured":"Barry F, Murphy M. Mesenchymal stem cells in joint disease and repair. Nat Rev Rheumatol. 2013;9(10):584\u201394.","journal-title":"Nat Rev Rheumatol"},{"issue":"3","key":"2631_CR9","first-page":"192","volume":"9","author":"LL Black","year":"2008","unstructured":"Black LL, Gaynor J, Adams C, Dhupa S, Sams AE, Taylor R, et al. Effect of intraarticular injection of autologous adipose-derived mesenchymal stem and regenerative cells on clinical signs of chronic osteoarthritis of the elbow joint in dogs. Vet Therap Res Appl Vet Med. 2008;9(3):192\u2013200.","journal-title":"Vet Therap Res Appl Vet Med"},{"issue":"11","key":"2631_CR10","doi-asserted-by":"publisher","first-page":"2964","DOI":"10.1634\/stemcells.2006-0311","volume":"25","author":"KB Lee","year":"2007","unstructured":"Lee KB, Hui JH, Song IC, Ardany L, Lee EH. Injectable mesenchymal stem cell therapy for large cartilage defects\u2013a porcine model. Stem Cells. 2007;25(11):2964\u201371.","journal-title":"Stem Cells"},{"issue":"12","key":"2631_CR11","doi-asserted-by":"publisher","first-page":"3464","DOI":"10.1002\/art.11365","volume":"48","author":"JM Murphy","year":"2003","unstructured":"Murphy JM, Fink DJ, Hunziker EB, Barry FP. Stem cell therapy in a caprine model of osteoarthritis. Arthritis Rheum. 2003;48(12):3464\u201374.","journal-title":"Arthritis Rheum"},{"issue":"9","key":"2631_CR12","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1002\/jor.22650","volume":"32","author":"GM van Buul","year":"2014","unstructured":"van Buul GM, Siebelt M, Leijs MJ, Bos PK, Waarsing JH, Kops N, et al. Mesenchymal stem cells reduce pain but not degenerative changes in a mono-iodoacetate rat model of osteoarthritis. J Orthop Res. 2014;32(9):1167\u201374.","journal-title":"J Orthop Res"},{"issue":"1","key":"2631_CR13","doi-asserted-by":"publisher","first-page":"81","DOI":"10.2174\/157488810790442796","volume":"5","author":"CJ Centeno","year":"2010","unstructured":"Centeno CJ, Schultz JR, Cheever M, Robinson B, Freeman M, Marasco W. Safety and complications reporting on the re-implantation of culture-expanded mesenchymal stem cells using autologous platelet lysate technique. Curr Stem Cell Res Ther. 2010;5(1):81\u201393.","journal-title":"Curr Stem Cell Res Ther"},{"issue":"5","key":"2631_CR14","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1002\/stem.1634","volume":"32","author":"CH Jo","year":"2014","unstructured":"Jo CH, Lee YG, Shin WH, Kim H, Chai JW, Jeong EC, et al. Intra-articular injection of mesenchymal stem cells for the treatment of osteoarthritis of the knee: a proof-of-concept clinical trial. Stem Cells. 2014;32(5):1254\u201366.","journal-title":"Stem Cells"},{"issue":"8","key":"2631_CR15","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1097\/TP.0000000000000678","volume":"99","author":"A Vega","year":"2015","unstructured":"Vega A, Mart\u00edn-Ferrero MA, Del Canto F, Alberca M, Garc\u00eda V, Munar A, et al. Treatment of knee osteoarthritis with allogeneic bone marrow mesenchymal stem cells: a randomized controlled trial. Transplantation. 2015;99(8):1681\u201390.","journal-title":"Transplantation"},{"issue":"3","key":"2631_CR16","first-page":"343","volume":"11","author":"CJ Centeno","year":"2008","unstructured":"Centeno CJ, Busse D, Kisiday J, Keohan C, Freeman M, Karli D. Increased knee cartilage volume in degenerative joint disease using percutaneously implanted, autologous mesenchymal stem cells. Pain Phys. 2008;11(3):343\u201353.","journal-title":"Pain Phys"},{"issue":"3","key":"2631_CR17","doi-asserted-by":"publisher","first-page":"295","DOI":"10.2217\/rme-2017-0152","volume":"13","author":"Y Song","year":"2018","unstructured":"Song Y, Du H, Dai C, Zhang L, Li S, Hunter DJ, et al. Human adipose-derived mesenchymal stem cells for osteoarthritis: a pilot study with long-term follow-up and repeated injections. Regen Med. 2018;13(3):295\u2013307.","journal-title":"Regen Med"},{"issue":"1","key":"2631_CR18","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1186\/s13287-019-1248-3","volume":"10","author":"L Lu","year":"2019","unstructured":"Lu L, Dai C, Zhang Z, Du H, Li S, Ye P, et al. Treatment of knee osteoarthritis with intra-articular injection of autologous adipose-derived mesenchymal progenitor cells: a prospective, randomized, double-blind, active-controlled, phase IIb clinical trial. Stem Cell Res Ther. 2019;10(1):143.","journal-title":"Stem Cell Res Ther"},{"issue":"6","key":"2631_CR19","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1002\/sctm.18-0122","volume":"8","author":"WS Lee","year":"2019","unstructured":"Lee WS, Kim HJ, Kim KI, Kim GB, Jin W. Intra-articular injection of autologous adipose tissue-derived mesenchymal stem cells for the treatment of knee osteoarthritis: a phase IIb, randomized, placebo-controlled clinical trial. Stem Cells Transl Med. 2019;8(6):504\u201311.","journal-title":"Stem Cells Transl Med"},{"issue":"3","key":"2631_CR20","doi-asserted-by":"publisher","first-page":"213","DOI":"10.2217\/rme-2018-0161","volume":"14","author":"J Freitag","year":"2019","unstructured":"Freitag J, Bates D, Wickham J, Shah K, Huguenin L, Tenen A, et al. Adipose-derived mesenchymal stem cell therapy in the treatment of knee osteoarthritis: a randomized controlled trial. Regen Med. 2019;14(3):213\u201330.","journal-title":"Regen Med"},{"key":"2631_CR21","unstructured":"Xinxin Han BY, Fagui Zou, Jianbo Sun. Clinical therapeutic efficacy of mesenchymal stem cells derived from adipose or bone marrow for knee osteoarthritis: a meta-analysis of randomized controlled trials. J Comp Eff Res. 2020."},{"issue":"1","key":"2631_CR22","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1186\/s13287-019-1406-7","volume":"10","author":"X Zhao","year":"2019","unstructured":"Zhao X, Ruan J, Tang H, Li J, Shi Y, Li M, et al. Multi-compositional MRI evaluation of repair cartilage in knee osteoarthritis with treatment of allogeneic human adipose-derived mesenchymal progenitor cells. Stem Cell Res Ther. 2019;10(1):308.","journal-title":"Stem Cell Res Ther"},{"key":"2631_CR23","doi-asserted-by":"crossref","unstructured":"Caplan H, Olson SD, Kumar A, George M, Prabhakara KS, Wenzel P, et al. Mesenchymal stromal cell therapeutic delivery: translational challenges to clinical application. 2019;10(1645).","DOI":"10.3389\/fimmu.2019.01645"},{"issue":"3","key":"2631_CR24","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nbt.2816","volume":"32","author":"JA Ankrum","year":"2014","unstructured":"Ankrum JA, Ong JF, Karp JM. Mesenchymal stem cells: immune evasive, not immune privileged. Nat Biotechnol. 2014;32(3):252\u201360.","journal-title":"Nat Biotechnol"},{"issue":"3","key":"2631_CR25","doi-asserted-by":"publisher","first-page":"305","DOI":"10.2217\/rme.15.14","volume":"10","author":"C Consentius","year":"2015","unstructured":"Consentius C, Reinke P, Volk HD. Immunogenicity of allogeneic mesenchymal stromal cells: what has been seen in vitro and in vivo? Regen Med. 2015;10(3):305\u201315.","journal-title":"Regen Med"},{"key":"2631_CR26","doi-asserted-by":"crossref","unstructured":"Berglund AK, Fortier LA, Antczak DF, Schnabel LV. Immunoprivileged no more: measuring the immunogenicity of allogeneic adult mesenchymal stem cells. Stem Cell Res Therapy. 2017;8(1):288.","DOI":"10.1186\/s13287-017-0742-8"},{"key":"2631_CR27","doi-asserted-by":"crossref","unstructured":"Lohan P, Treacy O, Griffin MD, Ritter T, Ryan AE. Anti-donor immune responses elicited by allogeneic mesenchymal stem cells and their extracellular vesicles: are we still learning? Front Immunol. 2017;8:1626.","DOI":"10.3389\/fimmu.2017.01626"},{"key":"2631_CR28","doi-asserted-by":"crossref","unstructured":"Ip HL, Nath DK, Sawleh SH, Kabir MH, Jahan N. Regenerative medicine for knee osteoarthritis\u2014the efficacy and safety of intra-articular platelet-rich plasma and mesenchymal stem cells injections: a literature review. Cureus. 2020;12(9):e10575.","DOI":"10.7759\/cureus.10575"},{"key":"2631_CR29","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1146\/annurev.pathmechdis.3.121806.151456","volume":"3","author":"KL Rock","year":"2008","unstructured":"Rock KL, Kono H. The inflammatory response to cell death. Annu Rev Pathol. 2008;3:99\u2013126.","journal-title":"Annu Rev Pathol"},{"issue":"1","key":"2631_CR30","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1186\/s13075-016-1195-7","volume":"18","author":"PK Gupta","year":"2016","unstructured":"Gupta PK, Chullikana A, Rengasamy M, Shetty N, Pandey V, Agarwal V, et al. Efficacy and safety of adult human bone marrow-derived, cultured, pooled, allogeneic mesenchymal stromal cells (Stempeucel(R)): preclinical and clinical trial in osteoarthritis of the knee joint. Arthritis Res Ther. 2016;18(1):301.","journal-title":"Arthritis Res Ther"},{"issue":"8","key":"2631_CR31","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1097\/TP.0000000000000678","volume":"99","author":"A Vega","year":"2015","unstructured":"Vega A, Martin-Ferrero MA, Del Canto F, Alberca M, Garcia V, Munar A, et al. Treatment of knee osteoarthritis with allogeneic bone marrow mesenchymal stem cells: a randomized controlled trial. Transplantation. 2015;99(8):1681\u201390.","journal-title":"Transplantation"},{"issue":"11\u201312","key":"2631_CR32","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1089\/ten.tea.2011.0544","volume":"18","author":"T Vinardell","year":"2012","unstructured":"Vinardell T, Sheehy EJ, Buckley CT, Kelly DJ. A comparison of the functionality and in vivo phenotypic stability of cartilaginous tissues engineered from different stem cell sources. Tissue Eng Part A. 2012;18(11\u201312):1161\u201370.","journal-title":"Tissue Eng Part A"},{"issue":"16","key":"2631_CR33","doi-asserted-by":"publisher","first-page":"7251","DOI":"10.1073\/pnas.1000302107","volume":"107","author":"C Scotti","year":"2010","unstructured":"Scotti C, Tonnarelli B, Papadimitropoulos A, Scherberich A, Schaeren S, Schauerte A, et al. Recapitulation of endochondral bone formation using human adult mesenchymal stem cells as a paradigm for developmental engineering. Proc Natl Acad Sci USA. 2010;107(16):7251\u20136.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2631_CR34","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.coph.2018.03.009","volume":"40","author":"C De Bari","year":"2018","unstructured":"De Bari C, Roelofs AJ. Stem cell-based therapeutic strategies for cartilage defects and osteoarthritis. Curr Opin Pharmacol. 2018;40:74\u201380.","journal-title":"Curr Opin Pharmacol"},{"issue":"14","key":"2631_CR35","doi-asserted-by":"publisher","first-page":"2724","DOI":"10.1089\/scd.2011.0722","volume":"21","author":"M Strioga","year":"2012","unstructured":"Strioga M, Viswanathan S, Darinskas A, Slaby O, Michalek J. Same or not the same? Comparison of adipose tissue-derived versus bone marrow-derived mesenchymal stem and stromal cells. Stem Cells Dev. 2012;21(14):2724\u201352.","journal-title":"Stem Cells Dev"},{"issue":"6","key":"2631_CR36","doi-asserted-by":"publisher","first-page":"455","DOI":"10.5966\/sctm.2012-0184","volume":"2","author":"SM Melief","year":"2013","unstructured":"Melief SM, Zwaginga JJ, Fibbe WE, Roelofs H. Adipose tissue-derived multipotent stromal cells have a higher immunomodulatory capacity than their bone marrow-derived counterparts. Stem Cells Transl Med. 2013;2(6):455\u201363.","journal-title":"Stem Cells Transl Med"},{"issue":"3","key":"2631_CR37","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1002\/sctm.18-0053","volume":"8","author":"J Matas","year":"2019","unstructured":"Matas J, Orrego M, Amenabar D, Infante C, Tapia-Limonchi R, Cadiz MI, et al. Umbilical cord-derived mesenchymal stromal cells (MSCs) for knee osteoarthritis: repeated MSC dosing is superior to a single MSC dose and to hyaluronic acid in a controlled randomized phase I\/II trial. Stem Cells Transl Med. 2019;8(3):215\u201324.","journal-title":"Stem Cells Transl Med"}],"container-title":["Stem Cell Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13287-021-02631-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13287-021-02631-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13287-021-02631-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,30]],"date-time":"2021-10-30T20:23:51Z","timestamp":1635625431000},"score":1,"resource":{"primary":{"URL":"https:\/\/stemcellres.biomedcentral.com\/articles\/10.1186\/s13287-021-02631-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,30]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2631"],"URL":"https:\/\/doi.org\/10.1186\/s13287-021-02631-z","relation":{},"ISSN":["1757-6512"],"issn-type":[{"value":"1757-6512","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,30]]},"assertion":[{"value":"1 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The protocol of the study was approved by the Institutional Review Board to the tenets of the Declaration of Helsinki. There were two study sites in this trial, including Linkou Chang Gung Memorial Hospital and Taipei Veterans General Hospital in Taiwan. The official ethical approval numbers of the study were 104-1182A (CGMF-IRB) and 2017\u201304-005A (VGHTPE-IRB). The study was registered at  (NCT02784964).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"562"}}